A ntipsychotic medications are widely used in the hospital setting for nonpsychiatric purposes, with recent studies demonstrating use in 6% to 9% of nonpsychiatric hospitalizations and 9% to 12% of those aged 75 and older, most often for management of delirium. [1] [2] [3] This practice has recently been questioned based on two systematic reviews, both concluding that current evidence does not support the use of antipsychotics for prevention or treatment of delirium. [4] [5] [6] Evidence of risk from antipsychotics, including falls 7, 8 and death, 9, 10 compounds concerns regarding lack of data supporting efficacy for this purpose. Concerns have also been raised regarding an association between antipsychotics and pneumonia through at least two hypothesized mechanisms. First, sedation, a known effect of antipsychotics, can lead to difficulty managing secretions and protecting the airway. 11, 12 Second, antipsychotics promote oropharyngeal dysphagia directly. 13, 14 Several observational studies have demonstrated an association between antipsychotics and pneumonia, particularly aspiration pneumonia, in older adults in the community, [15] [16] [17] [18] but these studies were casecontrol analyses and did not focus on hospitalized individuals, who have greater degrees of comorbidity and incidence of aspiration than people in the community, which could result in an even stronger association between antipsychotics and aspiration pneumonia in this population. Understanding the magnitude of any such association is important so that hospital physicians can incorporate this into their risk-to-benefit calculation when considering use of antipsychotics for nonpsychiatric, off-label purposes. Given that hospital-acquired pneumonia is common, costly, and morbid and disproportionately affects older adults, identifying potentially modifiable risk factors could result in better outcomes for hospitalized older adults. 19 In the present study, we investigated the association between antipsychotic exposure and aspiration pneumonia developing during hospitalization, hypothesizing that antipsychotic exposure would be associated with greater risk, particularly in older adults.
METHODS

Setting and Data Collection
We conducted a retrospective cohort study of individuals admitted to a large academic medical center in Boston, Massachusetts, from January 2007 through July 2013. The institutional review board at Beth Israel Deaconess Medical Center approved the study with a waiver of informed consent. Data were collected from electronic databases maintained at the medical center collected prospectively for clinical and administrative purposes and supplemented by chart review where noted.
Inclusion and Exclusion Criteria
All hospitalizations of individuals aged 18 and older were eligible for inclusion. We excluded outside hospital transfers because exposure data could not be obtained in this setting and those with a length of hospitalization less than 48 hours to allow sufficient time for development of nosocomial aspiration pneumonia. We also excluded those admitted to a psychiatry service or with a primary or secondary discharge diagnosis of a psychotic disorder, defined according to the Elixhauser comorbidity "Psychoses" (International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 295.00-298.9, 299.10-299.11 and Diagnosis-Related Groups 430 and 885) 20 because we were interested in use of antipsychotics for conditions other than primary psychiatric disorders.
Antipsychotic Use
In-hospital antipsychotic exposure was defined as any pharmacy charge for antipsychotic medication during the hospitalization. In a secondary analysis, we categorized antipsychotics as typical and atypical based on the classification of the Food and Drug Administration. 21, 22 We excluded prochlorperazine from our typical antipsychotic definition because it is used as an antiemetic rather than an antipsychotic.
Aspiration Pneumonia
The primary outcome was aspiration pneumonia acquired during hospitalization (occurring after the first 48 hours of hospitalization, consistent with the definition of nosocomial pneumonia 23 ). To identify cases, we reviewed the charts of all hospitalizations identified as having a discharge ICD-9-CM code for aspiration pneumonia (507) indicated as not present on admission. We validated that the treating clinician had made a clinical diagnosis of pneumonia and initiated antibiotics for this purpose. We also reviewed radiographs to confirm the presence of a new infiltrate in conjunction with the clinical diagnosis. Lastly, we reviewed the microbiologic data to determine whether there were any associated positive sputum cultures. We defined the date of pneumonia onset as the earliest date of initiation of antibiotics, positive radiograph, and positive sputum culture. A second member of the study team reviewed uncertain cases (with respect to presence of pneumonia or timing of diagnosis), and in the case of disagreement, a third member adjudicated. Only 15 cases of pneumonia (aspiration or nonaspiration, further described below) required adjudication by a third reviewer.
For hospitalizations with pneumonia, we censored observation time and medication exposure status on the date of pneumonia diagnosis. For antipsychotic exposure specifically, we performed a chart review to assure that exposures occurring on the same day as pneumonia preceded the pneumonia diagnosis. Receipt of mechanical ventilation and intensive care unit stay were censored the day before pneumonia diagnosis given the time required to develop infectious complications linked to these risk factors.
Covariates
Our models included variables hypothesized to predict use of antipsychotic medications and variables thought to increase risk of aspiration pneumonia based on prior literature and clinical grounds, including demographic variables such as age, sex, and race (self-reported by participants); hospitalization characteristic variables, including admitting department (medicine vs nonmedicine), whether the individual spent time in the intensive care unit and whether he or she received mechanical ventilation (including through tracheostomy); comorbidities, identified according to ICD-9-CM secondary diagnosis codes and DRGs using Healthcare Cost and Utilization Project (HCUP) Comorbidity Software, version 3.7, based on previous work, 20, 24 including paralysis and other neurological disorders; other clinical conditions, including delirium, dementia, insomnia, and acute cerebrovascular disease (see Supplementary Text S1 for ICD-9-CM codes); and use of other medications, including opioids, benzodiazepines, barbiturates, steroids, and acid-suppressive medications.
Statistical Analysis
The chi-square test was used to compare categorical variables and the independent samples t-test to compare continuous variables.
To determine the adjusted association between antipsychotic exposure (typical or atypical) and aspiration pneumonia, we used a multivariable generalized estimating equation (GEE) with logit link and first-order autoregressive correlation structure to control for confounders and to account for within-participant correlated data resulting from individuals having multiple hospitalizations. We controlled for all variables listed in Table 1 plus the HCUP comorbidities.
To assess the robustness of our findings, and in an attempt to achieve even more-homogenous comparator groups, we performed an additional analysis using propensity score matching. We derived a propensity score 25 using a GEE model in which antipsychotic exposure was the dependent variable. The same set of covariates was used as in the first approach. The fitted probability from this model was used as the propensity score, and the c-statistic was 0.83.
Hospitalizations were then matched on their propensity score using a greedy matching technique. 26 We calculated standardized differences to gauge effectiveness of the match. 27 Characteristics with residual imbalance (standardized difference absolute value >0.1) 28 were incorporated into a GEE model to obtain the adjusted odds ratio (OR) of aspiration pneumonia.
We evaluated the association between typical and atypical antipsychotic exposure and aspiration pneumonia using a GEE model controlling for all variables in Table 1 plus the HCUP comorbidities in which the independent variable of interest was a four-category variable reflecting no antipsychotic exposure (reference group), exposure to typical antipsychotics alone, exposure to atypical antipsychotics alone, and exposure to both.
A two-sided type 1 error of less than .05 indicated statistical significance. Assuming a rate of 0.5 cases of aspiration pneumonia per 100 hospitalizations and an exposure rate of 10% based on prior literature, a sample size of 150,000 hospitalizations would be necessary to achieve 90% power to detect a relative risk of 1.5. Analyses were carried out using SAS version 9.3 (SAS Institute, Inc., Cary, NC).
Sensitivity Analysis
Using methods similar to those of previous investigators, 29, 30 we estimated the strength of association (between an unmeasured confounder and antipsychotic use or an unmeasured confounder and aspiration pneumonia) that would be needed to explain the observed risk of aspiration pneumonia from antipsychotic use solely on the basis of confounding.
Specificity Analysis of Nonaspiration Pneumonia
Because it is hypothesized that antipsychotics cause pneumonia through effects on swallowing function, we hypothesized that antipsychotic medication would not be associated with nonaspiration pneumonia. To test this hypothesis, we reviewed the charts of all individuals with a discharge ICD-9-CM code for nonaspiration pneumonia (481, 482, 483, 485, 486) indicated as not present on admission, validating pneumonia occurrence and timing using the methodology described above. We then reran our analysis replacing aspiration with nonaspiration pneumonia as the dependent variable in our models. Subgroup Analyses: Age and Delirium or Dementia
To assess whether the relationship between antipsychotic exposure and aspiration pneumonia differed according to age category and to determine the attributable risk of aspiration pneumonia among these categories, we performed two additional analyses. First, we assessed for effect modification according to age by creating a three-category age variable (<65, 65-74, ≥75) and assessing the significance of the interaction term with antipsychotic exposure in our main model. Second, we ran stratified models of aspiration pneumonia in these predefined age categories. Because of sample sizes for these analyses, we had to remove covariates with low prevalence from our models to obtain convergence: peptic ulcer disease without bleeding, acquired immune deficiency syndrome (AIDS), solid tumor without metastasis, drug abuse, insomnia.
Because delirium and dementia are poorly captured in administrative databases, 31 and such misclassification could confound our analyses given that individuals with these conditions are more likely to be exposed to antipsychotics and more likely to aspirate, we repeated our analysis in the subgroup of hospitalizations with a discharge diagnosis of delirium or dementia. As a result of the smaller sample size, we had to remove covariates with low prevalence from our models to obtain convergence: peptic ulcer disease without bleeding, AIDS, insomnia.
RESULTS
Cohort Characteristics
There were 230,635 hospitalizations of individuals aged 18 and older from January 2007 through July 2013. After excluding outside hospital transfers (n = 14,422), hospitalizations shorter than 48 hours long (n = 59,774), and hospitalizations with psychosis or a psychiatric attending of record (n = 9,887), there were 146,552 hospitalizations in the cohort. The median age was 56 (range 18-107), and 56,734 (39%) were female. Table 1 shows the cohort characteristics stratified according to exposure status. (See  Supplementary Table S1 for the distribution of HCUP comorbidities.)
Exposure to Antipsychotic Medication
Antipsychotic exposure occurred in 10,377 (7.1%) hospitalizations, with a median of 3 days (interquartile range Table 1 ). Of the group exposed to antipsychotics, 3,677 (35.4%) received typical, 8,282 (79.8%) received atypical antipsychotics, and 1,582 (15.2%) received both. There were significant differences in baseline characteristics between those who were exposed and unexposed (Table 1) . Table 2 shows the unadjusted incidence of aspiration pneumonia relative to antipsychotic exposure. Aspiration pneumonia occurred in 557 hospitalizations (0.4%). For patients with antipsychotic exposure and aspiration pneumonia, there was a median of 1 day (IQR 0-2 days) between the last dose of antipsychotic medication and the diagnosis of aspiration pneumonia. The unadjusted incidence of aspiration pneumonia was higher in the group exposed to antipsychotics (1.2%) than in those who were unexposed (0.3%) (OR = 3.9, 95% confidence interval (CI) = 3.2-4.8).
Antipsychotic Medication and Aspiration Pneumonia
After adjustment, a significant association between antipsychotic exposure and aspiration pneumonia persisted (adjusted OR = (aOR) = 1.5, 95% CI = 1.2-1.9; Table 2 ).
Propensity-Matched Analysis
We successfully matched 10,203 (98.3%) hospitalizations with antipsychotic exposure to 10,203 unexposed hospitalizations. After matching, the group exposed to antipsychotics was much more similar in baseline characteristics to the unexposed group (Supplementary Table S1 ), with all standardized differences less than 0.1 except for age and depression, which we included in our postmatch GEE model. A significant association between antipsychotic exposure and aspiration pneumonia persisted (aOR = 1.4, 95% CI = 1.1-1.8; Table 2 ). Table 3 demonstrates the associations between subcategories of antipsychotics and aspiration pneumonia (typical: aOR = 1.4, 95% CI = 0.94-2.2; atypical: aOR = 1.5, 95% CI = 1.1-2.0).
Exposure Subcategories
Sensitivity Analysis
Assuming prevalence of a confounder of 20% (chosen because it resulted in the most conservative OR estimates), Matched on propensity score and analyzed using a multivariable GEE, controlling for all significantly imbalanced baseline characteristics after matching, as demonstrated in Table 3 (using a standardized difference (absolute value) >0.1). we found that ORs of at least 3 to 4 would be necessary between confounder and antipsychotic use and between confounder and aspiration pneumonia to explain our observed association solely on the basis of unmeasured confounding.
Specificity Analysis of Nonaspiration Pneumonia
We found no association between antipsychotic exposure and nonaspiration pneumonia using our traditional GEE (aOR = 1.1, 95% CI = 0.9-1.3) or propensity score (aOR = 1.0, 95% CI 0.8-1.2) approach ( Table 2 ).
Subgroup Analyses: Age and Delirium or Dementia
Antipsychotic exposure and aspiration pneumonia incidence increased significantly with age (<65, 65-74, ≥75: 5.2%, 7.3%, 12.5% exposure rate and 0.2%, 0.6%, 0.7% aspiration pneumonia incidence; P < .001 for both).
Although terms for effect modification according to age were not significant (P = .62 for interaction with age 65-74; P = .80 for interaction with age ≥75), the relative risk of aspiration pneumonia and the absolute incidence of aspiration pneumonia attributable to antipsychotic exposure increased with age ( Figure 1) . After restricting our analysis to hospitalizations with a discharge diagnosis of delirium or dementia (n = 9,516), the association was significant for aspiration pneumonia (aOR = 1.5, 95% CI = 1.1-2.1) but not for nonaspiration pneumonia (aOR = 0.8, 95% CI = 0.6-1.1).
DISCUSSION
In this cohort of nonpsychiatric hospitalizations at a large academic medical center, we found that antipsychotic exposure was associated with greater odds of aspiration pneumonia after extensive adjustment for participant characteristics. This association was robust through multiple analytical approaches and persisted when focusing on individuals with discharge diagnoses of delirium and dementia. The specificity of this association, demonstrated through our finding of no association between antipsychotics and nonaspiration pneumonia, lends support to the idea of a causal pathway between exposure and outcome. To our knowledge, this is the first study to evaluate the association between antipsychotic use and development of aspiration pneumonia in hospitalized individuals. This risk should be considered when prescribing antipsychotics in the hospital.
Recent systematic reviews have concluded that there is insufficient evidence to justify use of antipsychotics for prevention or treatment of delirium, mostly based on significant methodological limitations of existing studies and conflicting results. 4, 6 Nonetheless, when caring for individuals with severe agitation or distress who pose a risk of harm or interruption of medical therapy, hospital Adjusted for all variables listed in Table 1 , plus the Healthcare Cost and Utilization Project comorbidities, 24 using a multivariable generalized estimating equation to take into account dependency of the data due to repeated hospitalizations. OR = odds ratio; CI = confidence interval. Table 1 except insomnia, plus the Healthcare Cost and Utilization Project comorbidities with the exception of peptic ulcer disease without bleeding, acquired immune deficiency syndrome, solid tumor without metastasis, and drug abuse. (B) Adjusted absolute incidence of aspiration pneumonia attributable to antipsychotic exposure (attributable risk), calculated as the difference between the adjusted incidence of aspiration pneumonia in exposed and unexposed individuals, derived using Bayes theorem. Number needed to harm was calculated by taking the inverse of the attributable risk. Antipsychotic exposure and aspiration pneumonia incidence increased with age (<65, 65-74, ≥75: 5.2%, 7.3%, 12.5% exposed; 0.2%, 0.6%, 0.7% aspiration pneumonia incidence).
physicians are faced with few alternatives, and in this situation, most experts agree that the benefits of antipsychotics are likely to outweigh the risks. 5 However, antipsychotics are frequently used outside of this setting in hospitalized individuals. Our findings add to the increasingly recognized risks of antipsychotics, providing physicians with additional data to substantiate a higher threshold for use than is commonly employed and highlighting the importance of additional research to better define any benefits of these medications in delirium management.
Although the relationship between antipsychotic exposure and aspiration pneumonia did not differ significantly according to age based on a test for effect modification, the point estimates increased with age. Individuals aged 75 and older had more than triple the incidence of aspiration pneumonia than those younger than 65. Because of this, the absolute risk of aspiration pneumonia attributable to antipsychotic exposure (attributable risk) is much greater for older than younger adults. Accordingly, the number needed to harm is much smaller, dropping from more than 2,000 in those younger than 65 to 163 in those aged 75 and older. When coupled with our observation that individuals aged 75 and older had double the rate of antipsychotic exposure, our findings suggest that targeting older adults for interventions aimed at improving antipsychotic prescribing practices will lead to the greatest absolute reduction in the occurrence of this costly and morbid complication.
Because our study was observational, and thus prone to confounding by severity of illness and indication (wherein factors that make individuals more likely to be placed on antipsychotics also make them more likely to develop aspiration pneumonia, independent of the antipsychotic), we performed subgroup analyses designed to enhance comparability of hospitalizations with and without antipsychotic exposure, including a propensitymatched analysis and an analysis restricted to individuals with delirium or dementia. In both of these secondary analyses, the association between antipsychotic exposure and aspiration pneumonia was significant and consistent with our primary analysis. The robustness of this finding through multiple analyses supports the existence of a true association. Additionally, our sensitivity analysis determined that relatively strong associations (ORs of at least 3-4) between an unmeasured confounder and antipsychotic use and between confounder and aspiration pneumonia would be necessary to explain the risk observed in this study solely on the basis of unmeasured confounding. Nonetheless, we cannot exclude the possibility that unmeasured confounding (by indication or otherwise) explains our findings.
With an overall aspiration pneumonia rate of 0.4% and an antipsychotic exposure rate of 7%, a relative risk of 1.4 translates to an attributable risk of 0.16% and a number needed to harm of 625. With 40 million discharges from U.S. hospitals each year and approximately 2.8 million individuals exposed during hospitalization, this suggests that more than 4,000 excess cases of aspiration pneumonia may be attributable to hospital antipsychotic use each year.
We demonstrated qualitatively similar associations between typical and atypical antipsychotics and aspiration pneumonia. Prior analyses in the community and nursing home settings have yielded conflicting findings. Some have demonstrated greater risk in current users of atypical antipsychotics than of uses of typical antipsychotics, 15, 16 whereas others, including a metaanalysis of observational studies in the outpatient setting, have demonstrated similarly greater risk. [32] [33] [34] Our results lend support to the idea that pneumonia risk does not vary according to antipsychotic subclass.
Strengths of our study include the large sample size, chart-based validation of all cases of pneumonia, and rigorous methods to control for potential confounders. There are also important limitations. First, although we studied almost 150,000 hospitalizations, the single-center nature of the study limits generalizability, and our findings should be validated at other institutions. Additionally, lack of information on preadmission use of antipsychotic medications precluded our ability to assess for differential effects among new initiators. Two studies in the community setting found that pneumonia risk was highest during the first week after antipsychotic initiation. 15, 16 Because a study conducted at our medical center previously estimated that approximately half of antipsychotic use in hospitalized individuals represents new initiation, 2 it is possible that the inclusion of more-chronic use in our analysis could have resulted in underestimation of the true association between antipsychotic initiation and aspiration pneumonia.
In conclusion, in this large cohort of nonpsychiatric hospitalizations, antipsychotics were associated with 40% to 50% greater odds of developing aspiration pneumonia during hospitalization. This risk should be considered when prescribing antipsychotics for off-label purposes such as delirium and dementia in hospitalized individuals, particularly for those aged 75 and older. The controversial benefits of use in this setting must be weighed against the growing number of recognized risks.
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